Millions of people living with long-term neurological conditions across England face inconsistent access to vital rehabilitation services, according to NICE.
Around 5,000 blood cancer patients could benefit from 13 treatments recommended by NICE in 2024.
New combination therapy offers hope to 800 people annually with late-stage blood cancer.
At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.
We've published a draft quality standard calling for yearly BMI and waist-to-height measurements to help prevent weight-related complications.
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Page 12 of 46